A method for the determination of metanephrine (MN; also known as metadrenaline), normetanephrine (NMN; also known as normetadrenaline) and 3methoxytyramine (3-MT) in human urine using high-performance liquid chromatography followed by electrochemical detection (ECD) was validated primarily by comparing the results with those obtained by a gas chromatography±mass spectrometry (GC±MS) reference method. Correlation coef®cients of 0.93, 0.94 and 0.91 were obtained for MN, NMN and 3-MT, respectively, in a group of healthy controls consisting of 30 women and 30 men. A systematic difference was detected only for 3-MT (2 16%). Further tests of accuracy (linearity and recovery) and precision demonstrated that the described method must be considered to be a reliable approach to assess urinary metanephrines in the diagnosis of phaeochromocytoma. At lower concentrations (MN, 248 nmol/L; NMN, 434 nmol/L; 3-MT, 402 nmol/L), within-assay coef®cients of variation were close to 5% or less (5´3, 4´6 and 2´2%, respectively) and between-assay coef®cients of variation were 8´9, 11´2 and 12´3%, respectively, for the same low levels. This raises the possibility that this method can also be applied to assess urinary free, unconjugated metanephrines. Sex differences were detected for MN and NMN excretion when expressed in nmol per 24 h and nmol/mmol creatinine, respectively, by both ECD and GC±MS methods.
INTRODUCTION

Phaeochromocytomas
are catecholamineproducing tumours that arise from the chromaf®n cells of the adrenal medulla or from sympathetic ganglia (paraganglioma). Demonstration of excessive production of catecholamines and their metabolites is considered a hallmark in the biochemical diagnosis of catecholamine-producing tumours. Traditionally, these usually benign but potentially life-threatening tumours are biochemically diagnosed by the quanti®cation of catecholamines or their metabolites in either plasma or urine. Tests used to date for this purpose are those of plasma catecholamines, urinary free (unconjugated) catecholamines, urinary acidic catecholamine metabolites [notably vanillylmandelic acid (VMA)], and urinary total (sum of free and conjugated) metanephrines [normetanephrine (NMN; also known as normetadrenaline) and metanephrine (MN; also known as metadrenaline)]. 1, 2 Several studies have focused on the performance of these tests in the diagnosis of phaeochromocytoma. From these studies it has become clear that analysis of the ®nal urinary catecholamine metabolite VMA has a signi®cantly lower diagnostic value than that of urinary free catecholamines or urinary total metanephrines. 2±4 Recently obtained data and further understanding of catecholamine metabolism in cases of phaeochromocytoma have given a theoretical basis to the observation that analysis of metanephrines is helpful in the diagnosis and follow-up of the catecholamine-producing tumours. In a study of 52 patients with phaeochromocytoma, Lenders et al. showed that plasma free metanephrines had a diagnostic sensitivity of 100% and a speci®city of 85%. 5 Eisenhofer et al. 6 showed that membranebound catecholamine-O-methyltransferase, the enzyme responsible for conversion of catecholamines into their 3-O-methylatedmetabolites, is the predominant form of the enzyme present in phaeochromocytoma cells. It was shown that in phaeochromocytoma patients more than 90% of plasma free metanephrines are derived from metabolism before, not after, release of catecholamines into the circulation. From these results it was concluded that measurement of plasma free metanephrines would provide a more reliable marker for the presence of a phaeochromocytoma than that of the parent amines. Since measurement of plasma free metanephrines requires an extremely sensitive assay, measurement of urinary metanephrines must still be considered as the only possible alternative. Indeed, it has been noted 2,7 that one of the most sensitive and speci®c methods for the diagnosis and follow-up of patients with phaeochromocytoma remains the assay of urinary metanephrines, provided that the analysis is carried out by modern chromatographic techniques. Recent improvements in the instrumentation of clinical chemical laboratories have shifted the analyses from the classical uorometric and spectrophotometric methods towards high-performance liquid chromatography (HPLC)-based methods and immunoassay. 2, 7 These developments have signi®cantly improved the analytical sensitivity and speci®city of the assays. 4 In the present study, we describe the validation of a modi®ed HPLC-based method with electrochemical detection (ECD) for the determination of total (free+conjugated) urinary metanephrines. This method is compared with a previously described isotope dilution massspectrometric (MS) method. 8 Special attention is paid to detection limits in order to judge potential application for measurement of the free urinary moieties. We have established reference values using samples from 30 adult healthy women and 30 adult healthy men.
MATERIALS AND METHODS
Subjects and sample collection
A group of 60 healthy volunteers [30 men, age 446 14 (mean6 SD) years, range 21±64 years; 30 women, age 446 15 (mean6 SD) years, range 20±70 years] participated in the study. Before entry into the study all participants underwent clinical physical examination. None of the subjects was undergoing pharmacological treatment of any kind or suffered from cardiovascular or any major diseases. All subjects gave their informed consent and the study protocol was designed according to the directives set by the Ethics Committee of the University Medical Centre Nijmegen. Twenty-four-hour urine specimens were collected during the course of normal daily activities in 2-L polypropylene bottles containing 10 mL of 6 mol/L hydrochloric acid. Portions of the 24-h urine specimens were acidi®ed to pH 3 with 1 mol/L hydrochloric acid before partition into aliquots and freezing at 2 20°C. For the comparison study, these aliquots were transported on dry ice from the University Medical Centre Nijmegen to the University Hospital Groningen.
HPLC with electrochemical detection
This method was developed at the University Medical Centre Nijmegen with the use of the reagent kit (UMET by HPLC, code 195-6068) from BioRad Labs (Richmond CA, USA). The components denoted by the manufacturer as basic',`acidic',`hydrolysis',`dilution' and elution' reagents,`transfer buffer',`internal standard' (4-O-methyldopamine) and`cationand anion-exchange columns' were used. The actual composition of these reagents is not given in the enclosed instruction manual.
The following modi®cations were made to the BioRad procedure. A standard mixture consisting of 2´18 mmol/L NMN, 2´03 mmol/L MN and 2´39 mmol/L 3-methoxytyramine (3-MT) (pure substances purchased from Sigma, St Louis MO, USA) was combined with the internal standard (4-O-methyldopamine) included in the BioRad reagent kit as a substitute for the BioRad calibration mixture. The mobile phase consisted of 10 mg of 1-octane sulphonic acid (sodium salt) (Aldrich-Chemie, Steinheim, Germany), 60 mL of 1 mol/L KH 2 PO 4 (Merck, Darmstadt, Germany), 65 mL of acetonitrile (Far UV grade; Fisons, Loughborough, UK) and 900 mL of distilled water. Finally, H 3 PO 4 (Merck) after dilution to about 15% (v/v) was used to adjust the pH to 4´0.
Sample preparation was carried out as follows. To 1 mL of sample (standard and urine samples), 60 mL of working internal standard solution, 940 mL of 0´2 mol/L acetic acid and 2 mL of distilled water were added in a 162 100 mm disposable glass culture tube. The samples were adjusted to pH 1´0 with the`hydrolysis reagent' and the tubes were placed in a boiling water bath for 20 min. The hydrolysed samples were diluted with 5 mL of`dilution reagent' and the pH of the samples was adjusted to 6´5 with the BioRad basic' or`acidic' reagent. Subsequently, the samples were transferred to the`cation-exchange column' and allowed to pass through the column. After three successive washings of the column with 8´5 mL of distilled water, the amines were transferred to the`anion-exchange column' with 8 mL of`transfer buffer'. After washing the column once with 8´5 mL of distilled water, the amines were eluted from the resin with 5 mL of elution reagent' and 400 mL of`acidic reagent' was added to each eluate. Finally, 75 mL of the eluate was injected onto the column. The system con®guration consisted of a constaMetric 1 3200 Solvent Delivery System from LDC Analytical (FL, USA) and an automated sample processor WISP 717 plus (Waters Associates, Milford MA, USA). The separations were performed on a 5-mm analytical C18 Ultrasphere reversed-phase column (4´62 250 mm) ®tted with a 5-mm Inertsil ODS-2 C18 guard column. A Coulochem 2 Model 5100 detector (ESA, Bedford MA, USA) was used for the electrochemical detection of MN, NMN, 3-MT and 4-O-methyldopamine. No guard cell was used. An oxidizing potential of +400 mV was applied at the ®rst electrode of the analytical cell with a current of 500 nA to obtain an optimal signal-to-noise ratio. The¯ow-rate was 1´0 mL/min.
GC±isotope dilution MS method
An extensive description of the GC±isotope dilution MS method (University Hospital Groningen) for the assessment of urinary metanephrines has been given previously. 8 In this procedure, in contrast to the HPLC±ECD method, urine samples are not hydrolysed, but are lyophilized ®rst. In the subsequent step, free and conjugated metanephrines are converted into one single volatile derivative.
Creatinine
Urinary creatinine concentrations were measured by a modi®ed JaffeÂ method on an Hitachi 747 analyser (Boehringer, Mannheim, Germany).
Assessment of sensitivity, precision and accuracy Sensitivity
The detection limits for MN, NMN and 3-MT were obtained by calculating the concentration corresponding to a signal-to-noiseratio of 3 in the appropriate region of a typical chromatogram.
Precision
For the HPLC method, within-series and between-series precisions were calculated from duplicate estimates in ten consecutive assay runs with three pooled urines with low, medium and high normal concentrations of MN, NMN and 3-MT.
Accuracy
Assay accuracy was assessed in four different runs by determining in duplicate the recovery of additions of pure MN, NMN and 3-MT (to about 1´5 times the original level) to the three above-mentioned normal pooled urine samples. In addition, in the same two urine samples with low and high normal concentrations for MN, NMN and 3-MT and in 3:1, 1:1 and 1:3 mixtures of these two samples, four-fold measurements were made according to the NCCLS Evaluation Protocol 6 for linearity. 9 Where statistically signi®cant, the deviation from linearity was calculated as the difference between the total scatter of the dose points around the regression line and the residual error (within-assay precision obtained from the replicate measurements). This difference was expressed as a percentage of the dynamic range of the curve.
Calculations
The Baseline 810 Chromatography Workstation Version 3.30 software package (Millipore Corp., CA, USA) was used for HPLC±ECD peak analysis. With each series of samples, a standard mixture was analysed. Peak-height ratios for each analyte to the internal standard 4-Omethyldopamine were determined in both the standard mixture and the urine samples. From these ratios the concentrations in the urine samples can be calculated straightforwardly. For method comparison purposes, measurements were expressed in nmol/L. For comparison among subject groups, excretion was expressed both in nmol per 24 h and in nmol/mmol creatinine.
Statistics
Method comparisons between HPLC±ECD and GC±MS were carried out according to the regression procedure of Passing and Bablok 10 using the Eval-kit package (CKCHL Software, Tilburg, The Netherlands). Comparisons of MN, NMN and 3-MT excretion between the groups of control subjects were made by the Kolmogorov± Smirnov two-sample test in the SPSS (V.8, Gorinchem, The Netherlands) statistical package.
RESULTS
Typical chromatograms obtained by the HPLC method are shown in Fig. 1 .
Comparison of HPLC±ECD with GC±MS
Sixty urine samples, consisting of 30 samples obtained from healthy men and another 30 from healthy women were investigated. Figure 2 graphically displays the results of the comparison of HPLC±ECD versus GC±MS for MN, NMN and 3-MT. For MN and NMN, the slopes (MN, 1´01; NMN, 1´06) did not differ signi®cantly from 1 and the intercepts (MN, 2 7; NMN, 2 3´1) did not differ from 0. However,
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Sensitivity
The standard deviation of the baseline signal in a typical chromatogram recorded during 6´0± 7´5 min was 586 mV for the HPLC±ECD method.
De®ning the detection limit as the concentration that causes three times this value, detection limits of 1´85, 1´53 and 2´55 nmol/L were obtained for MN, NMN and 3-MT, respectively. These amounts corresponded to 0´026, 0´021 and 0´035 pmol on-column, respectively.
Precision Table 1 shows within-and between-assay precision for three urine samples with low, medium and high normal concentrations of MN, NMN and 3-MT. Within-and between-assay precisions were investigated by assaying in duplicate these three urine samples in ten different runs. The coef®cients of variation for the within-series precision for the three analytes ranged from 1´4% to 5´3% for MN, from 2´6% to 4´6% for NMN and from 1´6% to 2´7% for 3-MT for the HPLC±ECD method ( Table 1 ). The coef®cients of variation for the between-series precision ranged from 8´9% to 10´8% for MN, from 9´0% to 11´2% for NMN and from 10´2% to 12´3% for 3-MT for the HPLC±ECD method (Table 1 ). (Table 2) . Table 3 gives the magnitude of the deviations from linearity, expressed as a percentage of the concentration range between low and high samples, as well as the minimum detectable deviation from linearity calculated from the current assay precision. Statistically signi®cant departures from linearity were detected which, however, were small for MN and 3-MT (1´8 and 0´6%, respectively). Table 4 shows the 95% con®dence intervals for urinary total MN, NMN and 3-MT levels obtained from 60 healthy adults as assessed by HPLC±ECD. These values were (for clinical purposes) expressed either in nmol excreted in 24 h or in nmol/mmol creatinine. The data were analysed after logarithmic transformation. The mean (6 standard deviation, SD) of the 24-h volume was 18396 770 mL (with no signi®cant difference between men and women) and the mean (6 SD) creatinine concentration was 10´06 4´6 mmol/L for men and 6´56 3´3 mmol/L for women (P< 0´002). The data of the concentrations of MN, NMN and 3-MT followed more closely a log±normal than a normal distribution, so the between-group differences and the con-®dence intervals were assessed after logarithmic transformation. The excreted MN in 24 h was found to be signi®cantly higher in men than in women (P< 0´00005). However, when expressed in nmol/mmol creatinine, no differences were found. For the NMN excreted in 24 h, the average value of the subgroup of postmenopausal women (n=11) was just signi®cantly higher (P< 0´05) than the mean of the premenopausal group (n=19). When expressed in nmol/mmol creatinine, however, a highly signi®cant difference between men and women was encountered (P< 0´0001) and the difference between pre-and
Accuracy
Reference values
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Ann Clin Biochem 2001: 38 High and low samples were mixed in 1:0, 1:3, 1:1, 3:1 and 0:1 proportions and assayed in quadruplicate. The minimum detectable deviation from linearity depends on the standard deviation (SD) of the data points, i.e. the residual variation (within SD) or imprecision of the assay. NMN=normetanephrine; MN=metanephrine; 3-MT=3-methoxytyramine.
postmenopausal women now became highly signi®cant (ranges 70±235 and 120±300 nmol/ mmol creatinine, respectively; P< 0´0002). No differences between men and women were found for 3-MT when expressed in nmol per 24 h. However, when expressed in nmol/mmol creatinine, differences between men and women were found (P< 0´005). For the GC±MS method, comparable sex differences were found (data not shown). As a consequence of the high degree of conformity of the HPLC±ECD data with those of GC±MS, reference values measured by GC±MS were very similar to those summarized in Table 4 (measured by HPLC±ECD).
DISCUSSION
HPLC±ECD methodology was employed for the assessment of urinary MN, NMN and 3-MT and its performance was evaluated, especially by comparison of measurement results with those obtained by GC±MS.
Method comparisons and accuracy tests
Besides evaluation of precision and sensitivity, the HPLC±ECD method was validated by evaluating recoveries after spiking urine samples and by testing linearity using National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocol 6. The HPLC±ECD method correlated well with GC±MS for MN, NMN and 3-MT. No systematic difference for MN and NMN could be detected between ECD and GC± MS results. For 3-MT, the ECD results were 84% of those obtained by GC±MS.
The HPLC method relies on the internal standard that is added to both the standard preparation containing known concentrations of the analytes and the urine samples. The behaviour of these internal standards during the whole procedure relative to the analytes is of crucial importance for assay accuracy. 11 An internal standard works properly for a certain analyte only if there is, on a mole-to-mole basis, a constant ratio between the ®nal signal it yields to the signal elicited by the analyte, irrespective of whether these originate from the unknowns or the standard preparation. Such equal ratios may exist even when standards and samples are processed in different ways. However, identical processing generally is to be preferred. Systematically elevated or decreased values will be obtained if the standard material in the standard preparation yields a ratio different from that of the samples. Moreover, the ratio might differ between samples as well.
In that case the error is not just systematic but will vary in an unpredictable manner. Another consequence of this analytical notion is that a certain substance may be very well suited as an internal standard for one analyte but may yield spurious or systematically deviating results for another. The suitability of 4-O-methyldopamine as internal standard was tested both by comparison with a reference method and by spiking. All recoveries were reasonably close to 100% although there seemed to be a tendency towards higher recoveries in samples with lower analyte concentrations. These lower concentrations seemed to originate primarily from large volumes of 24-h urine samples. In the case of 3-MT, the complete recovery of added standard seems to contradict the ®ndings in unspiked urine samples of lower levels (84%) than with the GC±MS method. This may be attributed to the fact that the free form of the substance is added for assessment of the recovery. Urinary metanephrines are largely present in conjugated form. These conjugates are hydrolysed by acid treatment when prepared for HPLC±ECD. Preceding GC±MS, both moieties are converted into a common derivative. For neither process can the ef®ciency be adequately evaluated by assessing the recovery of added free metanephrines. Thus, because of differences in ef®ciency of conversion of the conjugated metanephrines, different results may be obtained for the two methods, despite quantitative recovery of the added free substance.
The within-assay as well as the between-assay precision (Table 1) for MN, NMN and 3-MT are acceptable. The mean concentration of MN in the 60 healthy volunteers was 473 nmol/L and 1057 nmol/L for NMN. The detection limits of 1´85 and 1´53 nmol/L for MN and NMN, respectively, are more than adequate for the present application but are also suf®cient for measurement of the two-to ten-fold lower (than total) concentrations of the free, unconjugated metanephrines. 12 Most probably, the latter moiety better re¯ects free metanephrines in plasma than the total urinary MN or NMN. Plasma free (and, to a lesser extent, total) metanephrines have been reported to be superior indicators of the presence of phaeochromocytoma because concentrations of both are elevated even in those cases where plasma norepinephrine (also known as noradrenaline) is not increased. This re¯ects the fact that O-methylation of catecholamines mainly occurs in the tumour before release into the circulation. 5, 6 Therefore, measurement of free urinary metanephrines would open new perspectives for further improvement of sensitivity and speci®city in the diagnosis of phaeochromocytoma.
The linearity test deserves some comment. First, one should be aware of the fact that, the higher the assay precision, the more sensitive the test is for minute deviations from linearity. Therefore, the minimum detectable deviation from linearity, as can be calculated from the variance of the four-fold determinations, was included in Table 3 . The EP6 results show a signi®cant deviation from linearity of 7´1% for NMN. This cannot be simply explained by a relative over-or under-estimation in either the low or the high sample. More likely, this also would have resulted in a linear plot. On the other hand, the results of the NCCLS Evaluation Protocol 6 for linearity for MN and 3-MT, in which deviations from linearity of only 1´8 and 0´6% were detected, show the very high precision with which the experiment was conducted.
Reference values
Earlier observations indicating sex differences for urinary metanephrines in healthy subjects have always been ambiguous. Kairisto et al. 13 reported sex differences for 24-h excretion of MN and NMN and an age effect for NMN. However, no parallel measurement of creatinine was available and the reference group consisted of hypertensive patients. Gerlo and Sevens 4 also reported different reference values (only expressed in nmol per 24 h) for men and women. We detected the differences with both assay methods. In the case of MN, the difference found for 24-h excretion, which completely disappears when expressed in terms of creatinine excretion, seems to be adequately explained by the larger male average body mass. The apparent sex difference in NMN excretion corrected for creatinine, however, must be ascribed to a sex difference in catecholamine metabolism. These sex differences are not expected to hamper diagnosis seriously because false negative or false positive results are not likely to be encountered for MN and NMN at the same time.
The difference observed between pre-and postmenopausal women for NMN excretion, although highly signi®cant when expressed in terms of creatinine, cannot be readily explained. Although not included in the reference ranges, menopausal status should be taken into account when interpreting values near the upper limit of the reference range. Further study will be required to shed more light on this phenomenon.
